Vivoryon Therapeutics N.V. (0R3M.L)

0,8630 +0,1430 (+19,86%) Alla chiusura: 05:44PM BST

Vivoryon Therapeutics N.V.

Weinbergweg 22
Halle 06120
Germany
49 345 555 9900
https://www.vivoryon.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 15

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Michael Schaeffer Ph.D.	Chief Business Officer, Member of the Management Board & Executive Director	315k	N/D	1969
Mr. Frank T. Weber M.D.	Chairman of the Management Board, CEO, Chief Medical Officer & Executive Director	N/D	N/D	1960
Ms. Anne Doering C.F.A.	CSO & Investor Relations Officer, CFO, Member of the Management Board and Executive Director	N/D	N/D	N/D
Dr. Manuela Bader	Director of Investor Relations & Communications	N/D	N/D	N/D
Dr. Konrad Glund	Co-Founder & Advisor	222,11k	N/D	1953
Dr. Hendrik Liebers	Advisor	319,2k	N/D	1971

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Governance aziendale

L'ISS Governance QualityScore di Vivoryon Therapeutics N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.